Accurate, balanced evidence-based information about medicines
Email this page
Print
Bookmark and share
Bigger
SmallerNPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals. NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Find out more about NPS RADAR.
RADAR review articles
Prasugrel (Effient) for acute coronary syndrome in people undergoing percutaneous coronary intervention
Prasugrel is an alternative to clopidogrel for acute coronary syndrome managed by percutaneous coronary intervention in combination with aspirin. It reduces the risk of atherothrombotic events more than clopidogrel, but at the expense of more bleeding.
Pramipexole (Sifrol) for early Parkinson’s disease
Pramipexole is a non-ergot dopamine agonist that is now listed for treating early Parkinson’s disease. Sleep attacks and compulsive behaviour have been reported with pramipexole and other dopamine agonists.
Olanzapine depot injection (Zyprexa Relprevv) for schizophrenia
Olanzapine pamoate is a long-acting injectable form of olanzapine. Post-injection syndrome can occur: monitor for signs and symptoms for at least 3 hours after administration.
In Brief
- Montelukast (Singulair) PBS listed for exercise-induced asthma in children aged 6–14 years
- Varenicline (Champix) safety update: serious neuropsychiatric and dermatological adverse events
- New pneumococcal polysaccharide conjugate vaccine (Synflorix) added to the national immunisation schedule
- Etoricoxib (Arcoxia): be aware of hypertension risk
- Authority listing for ciprofloxacin ear drops extended
The information contained in this material is derived from a critical analysis of a wide range of authoritative evidence. Any treatment decisions based on this information should be made in the context of the clinical circumstances of each patient.
RSS feed
